Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riboflavin Cross-linking at 9 and 18 mW/cm2 for Keratoconus
NCT02009709Phase 1Unknown
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of riboflavin in keratoconus and corneal ectasia. Primary endpoint: Maximum corneal curvature at 6 months. Status: unknown.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT02009709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009709.